Experimental and Analytical Dose Assessment of Patient's Family Members Treated with I-131

Authors: Marzieh Ebrahimi, Vahid Changizi, Mohammad Reza Kardan, Seyed Mahdi Hosseini Pooya, Parham Geramifar

Abstract:

Radiation exposure to the patient's family members is one of the major concerns during thyroid cancer radionuclide therapy. The aim of this study was to measure the total effective dose of the family members by means of thermoluminescence personal dosimeter, and compare with those calculated by analytical methods. Eighty-five adult family members of fifty-one patients volunteered to participate in this research study. Considering the minimum and maximum range of dose rate from 15 µsv/h to 120 µsv/h at patients' release time, the calculated mean and median dose values of family members were 0.45 mSv and 0.28 mSv, respectively. Moreover, almost all family members’ doses were measured to be less than the dose constraint of 5 mSv recommended by Basic Safety Standards. Considering the influence parameters such as patient dose rate and administrated activity, the total effective doses of family members were calculated by TEDE and NRC formulas and compared with those of experimental results. The results indicated that, it is fruitful to use the quantitative calculations for releasing patients treated with I-131 and correct estimation of patients' family doses.

Keywords: Effective dose, thermoluminescence, I-131, Thyroid cancer.

Digital Object Identifier (DOI): doi.org/10.5281/zenodo.1126337

References:

[1] Kitagawa W, Shimizu K, Akasu H, Tanaka S. (Endocrine surgery. The ninth report: the latest data on and clinical characteristics of the epidemiology of thyroid carcinoma). Journal of Nippon Medical School = Nippon Ika Daigaku zasshi. 2003;70(1):57-61.
[2] Maxon HR. Quantitative radioiodine therapy in the treatment of differentiated thyroid cancer. The quarterly journal of nuclear medicine: official publication of the Italian Association of Nuclear Medicine. 1999; 43(4):313-23.
[3] American Thyroid Association Guidelines Taskforce on Thyroid N, Differentiated Thyroid C, Cooper DS, Doherty GM, Haugen BR, Kloos RT, et al. Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid: official journal of the American Thyroid Association. 2009; 19(11):1167-214.
[4] American Thyroid Association Taskforce On Radioiodine S, Sisson JC, Freitas J, McDougall IR, Dauer LT, Hurley JR, et al. Radiation safety in the treatment of patients with thyroid diseases by radioiodine 131I: practice recommendations of the American Thyroid Association. Thyroid: official journal of the American Thyroid Association. 2011; 21(4):335-46.
[5] Barrington SF, Anderson P, Kettle AG, Gadd R, Thomson WH, Batchelor S, et al. Measurement of the internal dose to families of outpatients treated with 131I for hyperthyroidism. European journal of nuclear medicine and molecular imaging. 2008;35(11):2097-104.
[6] Grundel M, Kopka B, Schulz R. 131I exhalation by patients undergoing therapy of thyroid diseases. Radiation protection dosimetry. 2008; 129(4):435-8.
[7] Watanabe H. (Explanation of the draft, "release of patients after therapy with unsealed radionuclides" of the International Commission on Radiological Protection: the 2nd report). Nihon Hoshasen Gijutsu Gakkai zasshi. 2004;60(5):689-97.
[8] Collins BJ, Chiappetta G, Schneider AB, Santoro M, Pentimalli F, Fogelfeld L, et al. RET expression in papillary thyroid cancer from patients irradiated in childhood for benign conditions. The Journal of clinical endocrinology and metabolism. 2002;87(8):3941-6.
[9] Frigren S. Radiation Protection following Iodine-131 therapy (exposures due to out-patients or discharged in-patients) Directorate-General Environment, Nuclear Safety and Civil Protection. 1998(European Commission).
[10] International Commission on Radiological P. Release of patients after therapy with unsealed radionuclides. Annals of the ICRP. 2004;34(2):v-vi, 1-79.
[11] Criteria for the release of individuals administered radioactive materials--NRC. Final rule. Federal register. 1997;62(19):4120-33.
[12] Fesenko SV, Voigt G, Spiridonov SI, Sanzharova NI, Gontarenko IA, Belli M, et al. Analysis of the contribution of forest pathways to the radiation exposure of different population groups in the Bryansk region of Russia. Radiation and environmental biophysics. 2000;39(4):291-300.
[13] Authorities HotERpC. 131I therapy: Patient release criteria
[14] Likhtarev IA, Kovgan LN, Vavilov SE, Gluvchinsky RR, Perevoznikov ON, Litvinets LN, et al. Internal exposure from the ingestion of foods contaminated by 137Cs after the Chernobyl accident. Report 1. General model: ingestion doses and countermeasure effectiveness for the adults of Rovno Oblast of Ukraine. Health physics. 1996;70(3):297-317.
[15] Fatome M. (Management of accidental internal exposure). Journal de radiologie. 1994;75(11):571-5.
[16] Mathieu I, Caussin J, Smeesters P, Wambersie A, Beckers C. Recommended restrictions after 131I therapy: measured doses in family members. Health physics. 1999;76(2):129-36.
[17] Barrington SF, Kettle AG, O'Doherty MJ, Wells CP, Somer EJ, Coakley AJ. Radiation dose rates from patients receiving iodine-131 therapy for carcinoma of the thyroid. European journal of nuclear medicine. 1996;23(2):123-30.
[18] Grigsby PW, Siegel BA, Baker S, Eichling JO. Radiation exposure from outpatient radioactive iodine (131I) therapy for thyroid carcinoma. Jama. 2000;283(17):2272-4.